Systemic administration of human umbilical cord‑derived mesenchymal stem cells effectively ameliorates the outcomes of a critically ill elderly patient with COVID‑19 with multiple comorbidities: A case report

Chen,Hongjun; Chen,Hongjun; Zhang,Leisheng; Zhang,Leisheng; He,Zhixu; He,Zhixu; Wang,Dali; Wang,Dali; Liu,Lili; Liu,Lili; Zhang,Wei; Zhang,Wei; Chen,Tao; Chen,Tao; Dai,Zhihua; Dai,Zhihua; Han,Zhongchao; Han,Zhongchao; Chen,Miao; Chen,Miao

doi:10.3892/wasj.2020.70

Systemic administration of human umbilical cord‑derived mesenchymal stem cells effectively ameliorates the outcomes of a critically ill elderly patient with COVID‑19 with multiple comorbidities: A case report

Authors:
- Hongjun Chen
- Leisheng Zhang
- Zhixu He
- Dali Wang
- Lili Liu
- Wei Zhang
- Tao Chen
- Zhihua Dai
- Zhongchao Han
- Miao Chen
View Affiliations

Affiliations: Department of Intensive Care Unit, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China, Jiangxi Research Center of Stem Cell Engineering, Jiangxi Health‑Biotech Stem Cell Technology Co., Ltd., Shangrao, Jiangxi 334000, P.R. China, Department of Pediatrics, Zunyi Medical University, Zunyi, Guizhou 563006, P.R. China, Department of Burn and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China, Cerebrovascular Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China, Stem Cell Bank of Guizhou Province, Guizhou Health‑Biotech Biotechnology Co., Ltd., Guiyang, Guizhou 550000, P.R. China
Published online on: October 1, 2020 https://doi.org/10.3892/wasj.2020.70
Article Number: 29
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The outbreak of coronavirus disease 2019 (COVID‑19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has spread worldwide and has become a public health emergency, principally due to the severe inflammatory response and cytokine storm, as well as the deficiency of specific vaccines and antiviral drugs. Despite the fact that mesenchymal stem cells (MSCs) are acknowledged to possess unique immunomodulatory capabilities and have promising prospects in regenerative medicine, the efficacy of the use of MSCs on critically ill elderly patients with COVID‑19 is largely obscure. In the present study, a 75‑year‑old male patient critically ill with COVID‑19 was enrolled with multiple concomitant diseases, including hypertension (for >10 years), diabetes and coronary heart disease (for >1 year). Systemic infusions of 5x10⁷ human umbilical cord‑derived mesenchymal stem/stromal cells (hUC‑MSCs) were accomplished through intravenous injection every 3 days for 3 times following the consents of the patient and the relevant ethics committee. The clinical and functional outcomes, including general symptoms, vital signs, hemogram, chest radiography and the disease score, together with inflammatory factors and SARS‑CoV‑2 nucleic acid detection, were observed and dynamically recorded for 1 month. With the aid of hUC‑MSC administration, the severe COVID‑19‑associated symptoms of the elderly patient, and in particular, pneumonia and the cytokine storm were continuously ameliorated. Moreover, the outcomes of multiple concomitant diseases were improved, whereas no deterioration and secondary infections, such as fever and allergic reaction were observed. The present study thus indicated that hUC‑MSC administration can ameliorate the outcomes of patients with COVID‑19. This type of treatment may prove to be an ideal alternative option for the treatment of patients with COVID‑19, even for critically ill elderly patients with multisystemic complications.

View Figures

View References

1	Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, et al: First case of 2019 novel coronavirus in the United States. N Engl J Med. 382:929–936. 2020.PubMed/NCBI View Article : Google Scholar
2	Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R and Ge XY: The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect. 22:80–85. 2020.PubMed/NCBI View Article : Google Scholar
3	Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
4	Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al: Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 382:1199–1207. 2020.PubMed/NCBI View Article : Google Scholar
5	Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al: Epidemiological and Clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 395:507–513. 2020.PubMed/NCBI View Article : Google Scholar
6	Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 323:1061–1069. 2020.PubMed/NCBI View Article : Google Scholar
7	Jiang S, Du L and Shi Z: An emerging coronavirus causing pneumonia outbreak in Wuhan, China: Calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 9:275–277. 2020.PubMed/NCBI View Article : Google Scholar
8	Zhou Y, Hou Y, Shen J, Huang Y, Martin W and Cheng F: Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 6(14)2020.PubMed/NCBI View Article : Google Scholar
9	Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK, Drakoulis N and Tsatsakis A: Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review). Int J Mol Med. 46:467–488. 2020.PubMed/NCBI View Article : Google Scholar
10	Wan Y, Shang J, Graham R, Baric RS and Li F: Receptor recognition by the novel coronavirus from Wuhan: An analysis Based on Decade-long structural studies of SARS coronavirus. J Virol. 94:e00127–20. 2020.PubMed/NCBI View Article : Google Scholar
11	Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A and Li F: Structural basis of receptor recognition by SARS-CoV-2. Nature. 581:221–224. 2020.PubMed/NCBI View Article : Google Scholar
12	Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L and Wang X: Structure of the SARS-CoV-2 spike Receptor-binding domain bound to the ACE2 receptor. Nature. 581:215–220. 2020.PubMed/NCBI View Article : Google Scholar
13	Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 11:875–879. 2005.PubMed/NCBI View Article : Google Scholar
14	Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, et al: Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 11:216–228. 2020.PubMed/NCBI View Article : Google Scholar
15	Yu F, Du L, Ojcius DM, Pan C and Jiang S: Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 22:74–79. 2020.PubMed/NCBI View Article : Google Scholar
16	Zhou G and Zhao Q: Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 16:1718–1723. 2020.PubMed/NCBI View Article : Google Scholar
17	Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP and Chaicumpa W: COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 16:1232–1238. 2020.PubMed/NCBI View Article : Google Scholar
18	Shang L, Zhao J, Hu Y, Du R and Cao B: On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 395:683–684. 2020.PubMed/NCBI View Article : Google Scholar
19	Russell CD, Millar JE and Baillie JK: Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 395:473–475. 2020.PubMed/NCBI View Article : Google Scholar
20	Zhao Q, Zhang L, Wei Y, Yu H, Zou L, Huo J, Yang H, Song B, Wei T, Wu D, et al: Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute Graft-versus-host disease. Stem Cell Res Ther. 10(354)2019.PubMed/NCBI View Article : Google Scholar
21	Yao J, Chen N, Wang X, Zhang L, Huo J, Chi Y, Li Z and Han Z: Human supernumerary Teeth-derived apical papillary stem cells possess preferable characteristics and efficacy on hepatic fibrosis in mice. Stem Cells Int. 2020(6489396)2020.PubMed/NCBI View Article : Google Scholar
22	Lu S, Ge M, Zheng Y, Li J, Feng X, Feng S, Huang J, Feng Y, Yang D, Shi J, et al: CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia. Stem Cell Res Ther. 8(178)2017.PubMed/NCBI View Article : Google Scholar
23	Du W, Li X, Chi Y, Ma F, Li Z, Yang S, Song B, Cui J, Ma T, Li J, et al: VCAM-1+ placenta chorionic villi-derived mesenchymal stem cells display potent Pro-angiogenic activity. Stem Cell Res Ther. 7(49)2016.PubMed/NCBI View Article : Google Scholar
24	Huo J, Zhang L, Ren X, Li C, Li X, Dong P, Zheng X, Huang J, Shao Y, Ge M, et al: Multifaceted characterization of the signatures and efficacy of mesenchymal stem/stromal cells in acquired aplastic anemia. Stem Cell Res Ther. 11(59)2020.PubMed/NCBI View Article : Google Scholar
25	Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ and Cool SM: Concise review: Multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med. 6:2173–2185. 2017.PubMed/NCBI View Article : Google Scholar
26	Pourgholaminejad A, Aghdami N, Baharvand H and Moazzeni SM: The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cells. Cytokine. 85:51–60. 2016.PubMed/NCBI View Article : Google Scholar
27	Fan XL, Zhang Y, Li X and Fu QL: Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 77:2771–2794. 2020.PubMed/NCBI View Article : Google Scholar
28	Kfoury Y and Scadden DT: Mesenchymal cell contributions to the stem cell niche. Cell Stem Cell. 16:239–253. 2015.PubMed/NCBI View Article : Google Scholar
29	Darwish I, Mubareka S and Liles WC: Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther. 9:807–822. 2011.PubMed/NCBI View Article : Google Scholar
30	Zhang X, Yang Y, Zhang L, Lu Y, Zhang Q, Fan D, Zhang Y, Zhang Y, Ye Z and Xiong D: Mesenchymal stromal cells as vehicles of tetravalent bispecific tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan. J Hematol Oncol. 10(56)2017.PubMed/NCBI View Article : Google Scholar
31	Wei Y, Zhang L, Chi Y, Ren X, Gao Y, Song B, Li C and Han Z, Zhang L and Han Z: High-efficient generation of VCAM-1(+) mesenchymal stem cells with multidimensional superiorities in signatures and efficacy on aplastic anaemia mice. Cell Prolif. 53(e12862)2020.PubMed/NCBI View Article : Google Scholar
32	Wang L, Liu T, Liang R, Wang G, Liu Y, Zou J, Liu N, Zhang B, Liu Y, Ding X, et al: Mesenchymal stem cells ameliorate β cell dysfunction of human type 2 diabetic islets by reversing β cell dedifferentiation. EBioMedicine. 51(102615)2020.PubMed/NCBI View Article : Google Scholar
33	Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al: Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 8:420–422. 2020.PubMed/NCBI View Article : Google Scholar
34	Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, et al: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 395:565–574. 2020.PubMed/NCBI View Article : Google Scholar
35	Guarner J: Three emerging coronaviruses in two decades. Am J Clin Pathol. 153:420–421. 2020.PubMed/NCBI View Article : Google Scholar
36	Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, Usmani AM, Hajjar W and Ahmed N: Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 24:2012–2019. 2020.PubMed/NCBI View Article : Google Scholar
37	Forster P, Forster L, Renfrew C and Forster M: Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci USA. 117:9241–9243. 2020.PubMed/NCBI View Article : Google Scholar
38	Li X, Zai J, Zhao Q, Nie Q, Li Y, Foley BT and Chaillon A: Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol. 92:602–611. 2020.PubMed/NCBI View Article : Google Scholar
39	Riou J and Althaus CL: Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 25(2000058)2020.PubMed/NCBI View Article : Google Scholar
40	Colson P, Rolain JM and Raoult D: Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 55(105923)2020.PubMed/NCBI View Article : Google Scholar
41	Nazeam J, Mohammed EZ, Raafat M, Houssein M, Elkafoury A, Hamdy D and Jamil L: Based on principles and insights of COVID-19 epidemiology, genome sequencing, and pathogenesis: Retrospective analysis of sinigrin and Prolixin(RX) (Fluphenazine) provides Off-label drug candidates. SLAS Discov: Aug 17, 2020 (Epub ahead of print). doi: 10.1177/2472555220950236.
42	Zhang L, Wang H, Liu C, Wu Q, Su P, Wu D, Guo J, Zhou W, Xu Y, Shi L and Zhou J: MSX2 initiates and accelerates mesenchymal stem/stromal cell specification of hPSCs by regulating TWIST1 and PRAME. Stem Cell Reports. 11:497–513. 2018.PubMed/NCBI View Article : Google Scholar
43	Wei Y, Hou H, Zhang L, Zhao N, Li C, Huo J, Liu Y, Zhang W, Li Z, Liu D, et al: JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia. Stem Cell Res Ther. 10(186)2019.PubMed/NCBI View Article : Google Scholar
44	Soontararak S, Chow L, Johnson V, Coy J, Wheat W, Regan D and Dow S: Mesenchymal stem cells (MSC) derived from induced pluripotent stem cells (iPSC) equivalent to Adipose-derived MSC in promoting intestinal healing and microbiome normalization in mouse inflammatory bowel disease model. Stem Cells Transl Med. 7:456–467. 2018.PubMed/NCBI View Article : Google Scholar
45	Liang X, Ding Y, Zhang Y, Tse HF and Lian Q: Paracrine mechanisms of mesenchymal stem cell-based therapy: Current status and perspectives. Cell Transplant. 23:1045–1059. 2014.PubMed/NCBI View Article : Google Scholar
46	Ye J and Gimble JM: Regulation of stem cell differentiation in adipose tissue by chronic inflammation. Clin Exp Pharmacol Physiol. 38:872–878. 2011.PubMed/NCBI View Article : Google Scholar